Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis | Journal of Neurology, Neurosurgery & Psychiatry

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

JNNP 100

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Multiple sclerosis

Original research

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

Online download statistics by month:

Online download statistics by month: October 2022 to March 2024

	Abstract	Full	Pdf
Oct 2022	1948	124	70
Nov 2022	3365	195	128
Dec 2022	1307	117	74
Jan 2023	966	87	58
Feb 2023	819	53	34
Mar 2023	877	88	56
Apr 2023	502	28	22
May 2023	544	48	43
Jun 2023	556	39	30
Jul 2023	382	32	17
Aug 2023	407	30	21
Sep 2023	303	29	18
Oct 2023	518	50	27
Nov 2023	382	42	29
Dec 2023	436	30	28
Jan 2024	284	21	14
Feb 2024	416	21	21
Mar 2024	376	27	16
Total	14388	1061	706